Organic Active Ingredients TRIZ Cases

A multilayer pirfenidone dressing enables point-of-injury burn treatment with 48-72 hour controlled release to help prevent hypertrophic scarring.

Pyrazole derivatives are tuned to keep strong H4 receptor antagonism while lowering hERG inhibition and QT syndrome risk.

Combining RAD1901 with everolimus helps inhibit and regress resistant ER-positive tumors while reducing uterine, bone, and other off-target effects.

A barrier-separated multilayer tablet keeps olanzapine and samidorphan apart to limit impurities while enabling immediate release and reduced weight gain.

Selective SIK inhibitor compounds increase bone formation and bone mass while avoiding daily injections and reducing risks linked to PTH therapy.

Azaquinolones are tuned for selective PARP1 inhibition and blood-brain barrier penetration, improving cancer and CNS treatment safety.

Positive allosteric GABAA modulators based on azacyclo neurosteroids help regulate brain excitability for depression and postpartum depression.

Novel alkoxy-substituted GPR88 modulators improve pharmacokinetics and reduce off-target activity for neuropsychiatric treatment.

A topical ruboxistaurin formulation uses penetration enhancers and antioxidants to reduce hyperpigmentation while minimizing skin irritation.

Selective inner polymer layers in multilayer patch packaging limit keto acid and sulfoxide absorption, preserving transdermal drug efficacy.

Blocking SHP-1 and SHP-2 signaling in CAR T cells helps counter inhibitory receptors, improving tumor killing, cytokine secretion, and infiltration.

Fluidized bed granulation improves Compound A powder flow and cuts sticking, enabling high-load tablets with stable drug release.

Controlled oral minoxidil release maintains therapeutic serum levels longer, limiting peak-related adverse effects in hair loss treatment.

Co-culturing immature oocytes with ovarian support cells improves in vitro maturation and embryo viability beyond simple FSH spike-in.

Ertugliflozin lowers renal glucose reabsorption to cut heart failure and cardiovascular risk in diabetic patients with low hypoglycemia risk.

A pH-dependent polymer solid dispersion turns a poorly soluble crystalline tankyrase inhibitor into a more bioavailable pharmaceutical raw material.

A thienopyrimidine benzamide scaffold broadens CCR7-led chemokine blockade to curb metastasis while improving potency and side-effect balance.

Carboxy-benzimidazole GLP-1R agonists balance oral administration, receptor binding, and metabolic stability for NASH, obesity, and Type 2 diabetes.

An enzyme assay using xylenol chromophore and manganese catalyst measures acetaminophen accurately during NAC treatment without extraction.

Flavonoids such as naringenin boost saltiness and umami in reduced-sodium foods without the bitterness or off-flavors of common substitutes.

Targeted tedizolid-side-group changes boost oxazolidinone activity against MRSA and Streptococcus while preserving the core scaffold.

Combining TNO155 with a PD-1 inhibitor boosts anti-tumor immune response and improves lasting remission beyond single-agent therapy.

Quaternary ammonium NMN and NR salts improve precursor stability and solubility while raising cellular NAD+ levels at practical doses.

Administering a glucocorticoid receptor antagonist and tracking ACTH and cortisol changes helps distinguish ACTH-dependent from ACTH-independent Cushing's syndrome.

Telescoped synthesis removes chromatography and tin reagents to raise ferroportin inhibitor yield, purity, and process safety.

A rosin ester derivative and inorganic acid help a low-drug nonaqueous transdermal layer maintain skin penetration, adhesion, and manufacturability.

Weekly eteplirsen dosing induces exon 51 skipping to raise functional dystrophin in DMD while limiting adverse effects.

Targeting KARS1 with Formula 1 compounds suppresses immune and cancer cell migration where diverse migration modes limit existing drugs.

PEG-IL2 with glucocorticoid and low-molecular-weight hyaluronic acid boosts skin Tregs, reduces inflammation, and helps prevent relapse.

Defined crystalline benzoxazole forms improve oral dosage stability, purity, and manufacturability while reducing impurity-related toxicological risk.

A selective NaV1.8 inhibitor in solid dispersion tablets improves pain relief while reducing cardiac, muscle, and opioid-related risks.

Combining SHP2 inhibitor TNO155 with ribociclib blocks RTK signaling and cell cycle progression to extend tumor control in KRAS-mutant cancers.

Selective GIRK1/4 inhibition with naphthyridinone compounds treats atrial fibrillation while limiting ventricular arrhythmia risk.

2C compounds target 5-HT2A receptors to treat inflammatory disorders while limiting CNS exposure and psychoactive side effects.

Novel lipase inhibitor analogs sustain lipase suppression without repeated dosing, reducing lipotoxicity in pancreatitis, sepsis, and acne.

Vitamin K2 and D3 stabilize bioavailable silicon against acidic pH polymerization, preserving oral bioavailability for bone fragility care.

2',3'-diester-4'-cyano nucleosides broaden antiviral coverage across RSV, Ebola, Zika, and Dengue while reducing toxicity and cost barriers.

Softgel compositions balance relacorilant with lipid excipients to improve compatibility, stability, and oral bioavailability.

A five-hour bi-phasic subcutaneous furosemide infusion uses neutral pH and isosmotic formulation to reduce pain and improve fluid overload treatment.

A tuned lipid nanoparticle composition protects nucleic acids in plasma while improving intracellular delivery and therapeutic index.

Novel ALK inhibitor compounds use substituent changes to overcome resistance and improve treatment across ALK-positive cancers.

Ionizable amino lipids with PEG and structural lipids improve mRNA encapsulation, hepatocyte targeting, and low-immunogenic delivery.

Formula (I) compounds enhance eIF2B GEF activity and dimer stability to attenuate ISR signaling and reduce cellular stress.

Blocking P-selectin expression or activity with siRNA or antibodies suppresses epithelial cell proliferation and may help overcome cancer treatment resistance.

An omega-3 phospholipid empty liposome promotes tumor-site drug release while preserving liposome stability and blood retention.

A selective small-molecule CSF1R inhibitor depletes TAMs and shrinks TGCT tumors while avoiding off-target kinase toxicity and CSF1 buildup.

Distinct crystalline forms of Compound I use X-ray diffraction fingerprints to select high-purity polymorphs with better stability and therapeutic efficacy.

Engineered NMN derivatives improve intracellular NAD+ delivery and control, supporting disease treatment and cell survival.

An injectable PLGA-DMSO depot forms an in situ implant that gives immediate risperidone onset and steady 4-week plasma levels without oral dosing.

Substituted tricyclic compounds inhibit SOS1 upstream of RAS, expanding treatment options while attenuating downstream signaling in cancer.